Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
cocaine
pharmacotherapy
substance use
systematic review
Journal
Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
29
04
2019
accepted:
01
05
2019
pubmed:
12
6
2019
medline:
28
11
2020
entrez:
12
6
2019
Statut:
ppublish
Résumé
Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS'). Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. Prospero CRD42018085667.
Sections du résumé
BACKGROUND
Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder.
METHODS
We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS').
RESULTS
Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75).
DISCUSSION
Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored.
SR REGISTRATION
Prospero CRD42018085667.
Identifiants
pubmed: 31183685
doi: 10.1007/s11606-019-05074-8
pii: 10.1007/s11606-019-05074-8
pmc: PMC6854210
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Central Nervous System Agents
0
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Meta-Analysis
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2858-2873Subventions
Organisme : AHRQ HHS
ID : K12 HS022981
Pays : United States
Références
Lipari RN, Van Horn SL. Trends in substance use disorders among adults aged 18 or older. The CBHSQ Report, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville.
Goldstein RA, DesLauriers C, Burda A, Johnson-Arbor K. Cocaine: history, social implications, and toxicity: a review. Semin Diagn Pathol 2009;26(1):10–7.
doi: 10.1053/j.semdp.2008.12.001
Riezzo I, Fiore C, De Carlo D, Pascale N, Neri M, Turillazzi E, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem 2012;19(33):5624–46.
doi: 10.2174/092986712803988893
Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010(1):CD007024. doi: https://doi.org/10.1002/14651858.CD007024.pub2 .
Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2015(4):CD006754. doi: https://doi.org/10.1002/14651858.CD006754.pub4 .
Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2015(5):CD003352. doi: https://doi.org/10.1002/14651858.CD003352.pub4 .
Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016;9:CD007380. doi: https://doi.org/10.1002/14651858.CD007380.pub4 .
Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2016;3:CD006306. doi: https://doi.org/10.1002/14651858.CD006306.pub3 .
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi: https://doi.org/10.1371/journal.pmed1000097 . Available from: www.prisma-statement.org.
doi: 10.1371/journal.pmed1000097
pubmed: 19621072
pmcid: 2707599
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011 [cited 2017 March 24]. Available from: http://handbook.cochrane.org/ .
Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend 2016;158:1–7. doi: https://doi.org/10.1016/j.drugalcdep.2015.11.004 .
doi: 10.1016/j.drugalcdep.2015.11.004
pubmed: 26652899
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
doi: 10.1016/0197-2456(86)90046-2
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539–58. doi: https://doi.org/10.1002/sim.1186 .
doi: 10.1002/sim.1186
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60. doi: https://doi.org/10.1136/bmj.327.7414.557 .
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 12958120
Berkman N, Lohr K, Ansari M, McDonagh M, Balk E, Whitlock E, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Rockville: Agency for Healthcare Research and Quality; Methods Guide for Comparative Effectiveness Reviews (AHRQ Publication No. 13(14)-EHC130-EF), 2013.
Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev. 2011(12):CD002950. doi: https://doi.org/10.1002/14651858.CD002950.pub3 .
Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict 2014;23(1):68–75. doi: https://doi.org/10.1111/j.1521-0391.2013.12065.x.
doi: 10.1111/j.1521-0391.2013.12065.x.
pubmed: 24313244
Afshar M, Knapp CM, Sarid-Segal O, Devine E, Colaneri LS, Tozier L, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse 2012;38(2):181–6. doi: https://doi.org/10.3109/00952990.2011.644002.
doi: 10.3109/00952990.2011.644002.
pubmed: 22221171
pmcid: 5377928
Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 2014;34(2):234–9. doi: https://doi.org/10.1097/JCP.0000000000000062.
doi: 10.1097/JCP.0000000000000062.
pubmed: 24525654
pmcid: 4068618
Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, et al. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 2012;107(1):131–41. doi: https://doi.org/10.1111/j.1360-0443.2011.03552.x.
doi: 10.1111/j.1360-0443.2011.03552.x.
pubmed: 21707811
Moran LM, Phillips KA, Kowalczyk WJ, Ghitza UE, Agage DA, Epstein DH, et al. Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. Behav Pharmacol 2017;28(1):63–73. doi: https://doi.org/10.1097/FBP.0000000000000268 .
doi: 10.1097/FBP.0000000000000268
pubmed: 27755017
pmcid: 5233586
Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63(2):219–28. doi: https://doi.org/10.1001/archpsyc.63.2.219.
doi: 10.1001/archpsyc.63.2.219.
pubmed: 16461866
Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010;111(1–2):97–104. doi: https://doi.org/10.1016/j.drugalcdep.2010.04.006.
doi: 10.1016/j.drugalcdep.2010.04.006.
pubmed: 20537812
pmcid: 2930076
Walsh SL, Middleton LS, Wong CJ, Nuzzo PA, Campbell CL, Rush CR, et al. Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial. Drug Alcohol Depend 2013;130(1–3):150–7. doi: https://doi.org/10.1016/j.drugalcdep.2012.10.024.
doi: 10.1016/j.drugalcdep.2012.10.024.
pubmed: 23200303
Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry 2014;75(7):757–64. doi: https://doi.org/10.4088/JCP.13m08862.
doi: 10.4088/JCP.13m08862.
pubmed: 24911028
pmcid: 4125613
Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh Y-CM, Kintaudi PC, Charuvastra VC, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64(12):1440–8.
doi: 10.4088/JCP.v64n1207
Kahn R, Biswas K, Childress A-R, Shoptaw S, Fudala PJ, Gorgon L, et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009;103(1–2):59–64. doi: https://doi.org/10.1016/j.drugalcdep.2009.03.011.
doi: 10.1016/j.drugalcdep.2009.03.011.
pubmed: 19414226
pmcid: 2774896
Baldacara L, Cogo-Moreira H, Parreira BL, Diniz TA, Milhomem JJ, Fernandes CC, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2016;77(3):398–406. doi: https://doi.org/10.4088/JCP.14m09377
doi: 10.4088/JCP.14m09377
pubmed: 27046312
Johnson BA, Ait-Daoud N, Wang X-Q, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013;70(12):1338–46. doi: https://doi.org/10.1001/jamapsychiatry.2013.2295
doi: 10.1001/jamapsychiatry.2013.2295
pubmed: 24132249
Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75(3):233–40. doi: https://doi.org/10.1016/j.drugalcdep.2004.03.008
doi: 10.1016/j.drugalcdep.2004.03.008
pubmed: 15283944
Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013;133(1):94–9. doi: https://doi.org/10.1016/j.drugalcdep.2013.05.026
doi: 10.1016/j.drugalcdep.2013.05.026
pubmed: 23810644
pmcid: 3786029
Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands. Drug Alcohol Depend 2014;138:177–84. doi: https://doi.org/10.1016/j.drugalcdep.2014.02.024
doi: 10.1016/j.drugalcdep.2014.02.024
pubmed: 24629631
Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 2014;140:92–100. doi: https://doi.org/10.1016/j.drugalcdep.2014.03.033
doi: 10.1016/j.drugalcdep.2014.03.033
pubmed: 24814607
pmcid: 4431633
Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54(8):713–20.
doi: 10.1001/archpsyc.1997.01830200041006
Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005;162(2):340–9. doi: https://doi.org/10.1176/appi.ajp.162.2.340
doi: 10.1176/appi.ajp.162.2.340
pubmed: 15677600
Carroll KM, Nich C, Petry NM, Eagan DA, Shi JM, Ball SA. A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug Alcohol Depend 2016;160:135–42. doi: https://doi.org/10.1016/j.drugalcdep.2015.12.036
doi: 10.1016/j.drugalcdep.2015.12.036
pubmed: 26817621
pmcid: 4767616
Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend 2012;126(1–2):224–31. doi: https://doi.org/10.1016/j.drugalcdep.2012.05.019
doi: 10.1016/j.drugalcdep.2012.05.019
pubmed: 22695473
pmcid: 3461119
Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 2013;73(3):219–24. doi: https://doi.org/10.1016/j.biopsych.2012.07.011
doi: 10.1016/j.biopsych.2012.07.011
pubmed: 22906516
Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011;113(2–3):184–91. doi: https://doi.org/10.1016/j.drugalcdep.2010.07.022
doi: 10.1016/j.drugalcdep.2010.07.022
pubmed: 20828943
Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 2014;136:36–42. doi: https://doi.org/10.1016/j.drugalcdep.2013.12.007 .
doi: 10.1016/j.drugalcdep.2013.12.007
pubmed: 24462581
Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013;23(11):1401–7. doi: https://doi.org/10.1016/j.euroneuro.2013.05.014
doi: 10.1016/j.euroneuro.2013.05.014
pubmed: 23849431
Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, et al. A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. Am J Addict 2014;23(6):591–7. doi: https://doi.org/10.1111/j.1521-0391.2014.12146.x
doi: 10.1111/j.1521-0391.2014.12146.x
pubmed: 25251201
Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009;18(5):356–62. doi: https://doi.org/10.3109/10550490903077929
doi: 10.3109/10550490903077929
pubmed: 19874153
pmcid: 2907651
Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004;13(4):333–41. doi: https://doi.org/10.1080/10550490490480982
doi: 10.1080/10550490490480982
pubmed: 15370932
Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001;26(2):167–80.
doi: 10.1016/S0306-4603(00)00098-8
Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 1998;139(1–2):44–52.
doi: 10.1007/s002130050688
Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abus Treat 2008;34(4):378–90. doi: https://doi.org/10.1016/j.jsat.2007.05.011
doi: 10.1016/j.jsat.2007.05.011
Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction 2016;111(8):1416–27. doi: https://doi.org/10.1111/add.13375
doi: 10.1111/add.13375
pubmed: 26948856
pmcid: 4940267
Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O’Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011;36(3):217–21. doi: https://doi.org/10.1016/j.addbeh.2010.11.003
doi: 10.1016/j.addbeh.2010.11.003
pubmed: 21112155
Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19(5):401–8. doi: https://doi.org/10.1111/j.1521-0391.2010.00066.x
doi: 10.1111/j.1521-0391.2010.00066.x
pubmed: 20716302
pmcid: 2966972
Plebani JG, Lynch KG, Yu Q, Pettinati HM, O’Brien CP, Kampman KM. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 2012;121(1–2):163–6. doi: https://doi.org/10.1016/j.drugalcdep.2011.08.025
doi: 10.1016/j.drugalcdep.2011.08.025
pubmed: 21925806
Malcolm R, LaRowe S, Cochran K, Moak D, Herron J, Brady K, et al. A controlled trial of amlodipine for cocaine dependence: a negative report. J Subst Abus Treat 2005;28(2):197–204. doi: https://doi.org/10.1016/j.jsat.2004.12.006
doi: 10.1016/j.jsat.2004.12.006
Sofuoglu M, Poling J, Babuscio T, Gonsai K, Severino K, Nich C, et al. Carvedilol does not reduce cocaine use in methadone-maintained cocaine users. J Subst Abus Treat 2017;73:63–9. doi: https://doi.org/10.1016/j.jsat.2016.11.005
doi: 10.1016/j.jsat.2016.11.005
Reid MS, Angrist B, Baker S, Woo C, Schwartz M, Montgomery A, et al. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:32–42. doi: https://doi.org/10.1111/j.1360-0443.2005.00989.x .
doi: 10.1111/j.1360-0443.2005.00989.x
pubmed: 15730348
Licata SC, Penetar DM, Ravichandran C, Rodolico J, Palmer C, Berko J, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med 2011;5(1):57–64. doi: https://doi.org/10.1097/ADM.0b013e3181d80c93
doi: 10.1097/ADM.0b013e3181d80c93
pubmed: 21769048
pmcid: 3140015
Kennedy AP, Gross RE, Whitfield N, Drexler KPG, Kilts CD. A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. Addict Behav 2012;37(8):900–7. doi: https://doi.org/10.1016/j.addbeh.2012.03.008
doi: 10.1016/j.addbeh.2012.03.008
pubmed: 22578380
pmcid: 3366369
Shoptaw S, Majewska MD, Wilkins J, Twitchell G, Yang X, Ling W. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Exp Clin Psychopharmacol 2004;12(2):126–35. doi: https://doi.org/10.1037/1064-1297.12.2.126
doi: 10.1037/1064-1297.12.2.126
pubmed: 15122957
Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend 2013;131(1–2):66–70. doi: https://doi.org/10.1016/j.drugalcdep.2012.11.021
doi: 10.1016/j.drugalcdep.2012.11.021
pubmed: 23306096
pmcid: 3655111
Sofuoglu M, Carroll KM. Effects of galantamine on cocaine use in chronic cocaine users. Am J Addict 2011;20(3):302–3. doi: https://doi.org/10.1111/j.1521-0391.2011.00130.x
doi: 10.1111/j.1521-0391.2011.00130.x
pubmed: 21477060
pmcid: 3073598
Margolin A, Kantak K, Copenhaver M, Avants SK. A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. J Addict Dis 2003;22(2):49–61. doi: https://doi.org/10.1300/J069v22n02_04
doi: 10.1300/J069v22n02_04
pubmed: 12703668
Reid MS, Angrist B, Baker SA, O’Leary S, Stone J, Schwartz M, et al. A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. Subst Abus 2005;26(2):5–14.
doi: 10.1300/J465v26n02_02
Kablinger AS, Lindner MA, Casso S, Hefti F, DeMuth G, Fox BS, et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol 2012;26(7):973–81. doi: https://doi.org/10.1177/0269881111430745
doi: 10.1177/0269881111430745
pubmed: 22236504
Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72(11):950–6. doi: https://doi.org/10.1016/j.biopsych.2012.05.032
doi: 10.1016/j.biopsych.2012.05.032
pubmed: 22795453
pmcid: 3648884
LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict 2013;22(5):443–52. doi: https://doi.org/10.1111/j.1521-0391.2013.12034.x
doi: 10.1111/j.1521-0391.2013.12034.x
pubmed: 23952889
pmcid: 4348575
Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006;84(3):256–63. doi: https://doi.org/10.1016/j.drugalcdep.2006.02.011
doi: 10.1016/j.drugalcdep.2006.02.011
pubmed: 16631323
Schmitz JM, Green CE, Hasan KM, Vincent J, Suchting R, Weaver MF, et al. PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction 2017;112(10):1861–8. doi: https://doi.org/10.1111/add.13868
doi: 10.1111/add.13868
pubmed: 28498501
pmcid: 5593771
Kampman K, Majewska MD, Tourian K, Dackis C, Cornish J, Poole S, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003;28(3):437–48.
doi: 10.1016/S0306-4603(02)00226-5
Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol 2007;15(5):453–60. doi: https://doi.org/10.1037/1064-1297.15.5.453
doi: 10.1037/1064-1297.15.5.453
pubmed: 17924779
Kampman KM, Volpicelli JR, Mulvaney F, Alterman AI, Cornish J, Gariti P, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63(1):69–78.
doi: 10.1016/S0376-8716(00)00193-9
Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. Drug Alcohol Depend 2016;166:13–20. doi: https://doi.org/10.1016/j.drugalcdep.2016.05.019
doi: 10.1016/j.drugalcdep.2016.05.019
pubmed: 27394932
Castells X, Kosten TR, Capella D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse 2009;35(5):339–49. doi: https://doi.org/10.1080/00952990903108215
doi: 10.1080/00952990903108215
Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2018. Designed by LM Rossen, A Lipphardt, FB Ahmad, JM Keralis, and Y Chong: National Center for Health Statistics. Available from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm .
Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction 2016;111(8):1337–46. doi: https://doi.org/10.1111/add.13328
doi: 10.1111/add.13328
pubmed: 26826006
McCall Jones C, Baldwin GT, Compton WM. Recent Increases in Cocaine-Related Overdose Deaths and the Role of Opioids. Am J Public Health 2017;107(3):430–2. doi: https://doi.org/10.2105/ajph.2016.303627 .
doi: 10.2105/ajph.2016.303627
pubmed: 28177817
pmcid: 5296707
Leeman RF, Sun Q, Bogart D, Beseler CL, Sofuoglu M. Comparisons of Cocaine-Only, Opioid-Only, and Users of Both Substances in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Subst Use Misuse 2016;51(5):553–64. doi: https://doi.org/10.3109/10826084.2015.1122063 .
doi: 10.3109/10826084.2015.1122063
pubmed: 27002858
pmcid: 5097614
Phillips KA, Epstein DH, Preston KL. Psychostimulant addiction treatment. Neuropharmacology. 2014;87:150-60. https://doi.org/10.1016/j.neuropharm.2014.04.002 .
doi: 10.1016/j.neuropharm.2014.04.002
pubmed: 24727297
pmcid: 4524548
Minozzi S, Saulle R, De Crescenzo F, Amato L. Psychosocial interventions for psychostimulant misuse. Cochrane Database Syst Rev 2016;9:CD011866. doi: https://doi.org/10.1002/14651858.CD011866.pub2 .
doi: 10.1002/14651858.CD011866.pub2
pubmed: 27684277
Klimas J, Wood E, Werb D. How can we investigate the role of topiramate in the treatment of cocaine use disorder more thoroughly? Addiction 2017;112(1):182–3. doi: https://doi.org/10.1111/add.13618.
doi: 10.1111/add.13618.
pubmed: 27813211
Darke S, Farrell M. Commentary on Singh et al. (2016): Still searching for the answer. Addiction 2016;111(8):1347. doi: https://doi.org/10.1111/add.13369.
doi: 10.1111/add.13369.
pubmed: 27396462
Chan B, Kondo K, Ayers C, Freeman M, Montgomery J, Paynter R, et al. Pharmacotherapy for Stimulant Use Disorders: A Systematic Review of the Evidence. VA ESP Project 05–225; 2018.
Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003;7(41):1–90
doi: 10.3310/hta7410
Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009;166(11):1269–77. doi: https://doi.org/10.1176/appi.ajp.2009.08121811
doi: 10.1176/appi.ajp.2009.08121811
pubmed: 19651710
Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013;70(6):630–7. doi: https://doi.org/10.1001/jamapsychiatry.2013.872
doi: 10.1001/jamapsychiatry.2013.872
pubmed: 23575810
George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000;47(12):1080–6.
doi: 10.1016/S0006-3223(99)00310-8
Petrakis IL, Carroll KM, Nich C, Gordon LT, McCance-Katz EF, Frankforter T, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000;95(2):219–28.
doi: 10.1046/j.1360-0443.2000.9522198.x